ResMed, Inc. (NYSE:RMD) will speak at the Piper Jaffray Health Care Conference on Wednesday, December 2. The conference will be held at the New York Palace Hotel in New York City. The company will begin its presentation at 9:00 am ET that morning. Interested parties may hear ResMed’s presentation via webcast on the company’s Investor Relations website at http://investor.resmed.com.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
ResMed Inc. is a holding company. Through its subsidiaries, the Company develops, manufactures and distributes medical equipment for treating, diagnosing and managing sleep-disordered breathing (SDB) and other respiratory disorders, including obstructive sleep apnea (OSA). It has developed nasal continuous positive airway pressure (CPAP) as a non-invasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. The Company has developed a number of products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. ResMed Inc. sells its products in over 70 countries through a combination of wholly owned subsidiaries and independent distributors to sleep clinics, home healthcare dealers and third-party payers. On April 30, 2009, it acquired Respicure Medsys PVT.LTD. In October 2009, ResMed Inc. acquired Laboratoires Narval.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
